Biomerica Stock Forecast, Price & News

+0.45 (+10.71 %)
(As of 09/17/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume139,137 shs
Average Volume284,843 shs
Market Capitalization$58.17 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive BMRA News and Ratings via Email

Sign-up to receive the latest news and ratings for Biomerica and its competitors with MarketBeat's FREE daily newsletter.

Biomerica logo

About Biomerica

Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The firm focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, United States, Asia, South America, Middle East, and Other. The company was founded in September 1971 and is headquartered in Irvine, CA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.94 out of 5 stars

Medical Sector

625th out of 1,351 stocks

Diagnostic Substances Industry

8th out of 25 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Biomerica (NASDAQ:BMRA) Frequently Asked Questions

Is Biomerica a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biomerica in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Biomerica stock.
View analyst ratings for Biomerica
or view top-rated stocks.

What stocks does MarketBeat like better than Biomerica?

Wall Street analysts have given Biomerica a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Biomerica wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Biomerica?

Biomerica saw a increase in short interest in the month of July. As of July 30th, there was short interest totaling 1,120,000 shares, an increase of 13.5% from the July 15th total of 986,900 shares. Based on an average trading volume of 321,000 shares, the short-interest ratio is presently 3.5 days. Approximately 11.0% of the company's stock are short sold.
View Biomerica's Short Interest

When is Biomerica's next earnings date?

Biomerica is scheduled to release its next quarterly earnings announcement on Thursday, October 21st 2021.
View our earnings forecast for Biomerica

How were Biomerica's earnings last quarter?

Biomerica, Inc. (NASDAQ:BMRA) announced its earnings results on Thursday, April, 29th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.07. Biomerica had a negative trailing twelve-month return on equity of 59.47% and a negative net margin of 89.83%.
View Biomerica's earnings history

How has Biomerica's stock been impacted by Coronavirus (COVID-19)?

Biomerica's stock was trading at $2.90 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BMRA stock has increased by 60.3% and is now trading at $4.65.
View which stocks have been most impacted by COVID-19

What price target have analysts set for BMRA?

3 equities research analysts have issued 1 year target prices for Biomerica's shares. Their forecasts range from $10.00 to $13.00. On average, they expect Biomerica's stock price to reach $11.33 in the next twelve months. This suggests a possible upside of 143.7% from the stock's current price.
View analysts' price targets for Biomerica
or view top-rated stocks among Wall Street analysts.

Who are Biomerica's key executives?

Biomerica's management team includes the following people:
  • Zackary S. Irani, Chairman & Chief Executive Officer
  • Steve Sloan, Chief Financial Officer
  • Allen C. Barbieri, Executive Vice Chairman & Secretary
  • Joshua S. Horowitz, Board Observer

Who are some of Biomerica's key competitors?

What other stocks do shareholders of Biomerica own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biomerica investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Johnson & Johnson (JNJ), Ampio Pharmaceuticals (AMPE), OPKO Health (OPK), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), Co-Diagnostics (CODX), FuelCell Energy (FCEL) and Trevena (TRVN).

What is Biomerica's stock symbol?

Biomerica trades on the NASDAQ under the ticker symbol "BMRA."

Who are Biomerica's major shareholders?

Biomerica's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.72%), M&G Investment Management Ltd. (1.33%), Fore Capital LLC (1.10%), GSA Capital Partners LLP (0.85%), Geode Capital Management LLC (0.60%) and State Street Corp (0.44%). Company insiders that own Biomerica stock include Catherine Coste and Mark A Sirgo.
View institutional ownership trends for Biomerica

Which institutional investors are selling Biomerica stock?

BMRA stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., and Susquehanna International Group LLP.
View insider buying and selling activity for Biomerica
or view top insider-selling stocks.

Which institutional investors are buying Biomerica stock?

BMRA stock was acquired by a variety of institutional investors in the last quarter, including M&G Investment Management Ltd., GSA Capital Partners LLP, Fore Capital LLC, State Street Corp, Simplex Trading LLC, GWM Advisors LLC, Orion Capital Management LLC, and XTX Topco Ltd.
View insider buying and selling activity for Biomerica
or or view top insider-buying stocks.

How do I buy shares of Biomerica?

Shares of BMRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biomerica's stock price today?

One share of BMRA stock can currently be purchased for approximately $4.65.

How much money does Biomerica make?

Biomerica has a market capitalization of $58.17 million and generates $7.20 million in revenue each year. The company earns $-6,470,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis.

How many employees does Biomerica have?

Biomerica employs 45 workers across the globe.

What is Biomerica's official website?

The official website for Biomerica is

Where are Biomerica's headquarters?

Biomerica is headquartered at 17571 Von Karman Avenue, Irvine CA, 92614.

How can I contact Biomerica?

Biomerica's mailing address is 17571 Von Karman Avenue, Irvine CA, 92614. The company can be reached via phone at (949) 645-2111.

This page was last updated on 9/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.